For laboratory use only. This product is intended for animal research only and not for use in humans.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
|Fluorescent Agent Type||Targeted|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||XenoLight|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Arthritis, Inflammation, Oncology/Cancer|
|Wave Length||750 nm|
XenoLight RediJect 2-DeoxyGlucosone (DG)-750 is a fluorescent,probe for in vivo targeting of tumors that typically exhibit elevated,glucose uptake rate in comparison to surrounding tissues. To achieve,maximum glucose targeting and enhanced tumor uptake, the probe,has been designed to contain four 2-DG molecules per dye molecule.,As indicated in Figure 1, RediJect 2-DG-750 probe showed specific,accumulation to LL-2 tumors shortly after delivery. In addition, specific,tumor labeling with the RediJect 2-DG-750 probe has also been,demonstrated with Breast (MDA-MB-231) Prostate (PC-3M) and Lung,(NCI-H460) tumors, further validating the utility of this probe as a generic fluorescence reagent for in vivo tumor targeting.
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.